-
Notice of AGM and posting of Report & Accounts
ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2020, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website…
-
Director Retirement
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Dr Robert Zimmer, President & Chief Science Officer has confirmed to the Company that he will not be seeking re-election at the forthcoming Annual General Meeting scheduled for 28 June 2021 and will be retiring from ImmuPharma PLC and…
-
FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2020 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £5.9m (31 December 2019: £1.4m) –…
-
Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease. As indicated in the 20 November 2020 announcement, Avion Pharmaceuticals (“Avion”), ImmuPharma’s licensing partner for Lupuzor™,…
-
Appointment of Company Secretary
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company’s Financial Controller, was appointed as Company Secretary on 15 January 2021. To download announcement click here
-
ImmuPharma to present at Biotech Showcase™ Digital 2021
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma’s Chief Operating Officer, will be presenting at the prestigious Biotech Showcase™ Digital 2021. The event will be virtually held between 11 and 15 January 2021. As part of ImmuPharma’s participation, an on-demand Company presentation has been provided in advance…
-
Total Share Capital Notification
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company’s Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting…
-
Grant of Share Options & PDMR dealing
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company (“Ordinary Shares”) to Directors, employees and consultants representing 3.8% of ImmuPharma’s Ordinary Shares and total voting rights (the “Options”). ImmuPharma…
-
Conversion of Convertible Security
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Lind Global Macro Fund, LP (“Lind”) has converted $355,112.50 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11…
